Current Edition

Acceleron

Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia takeout: Bloomberg

It wasn’t long ago that Bristol Myers Squibb ran the numbers on potentially buying Acceleron Pharma, but that deal didn’t come together, and the biotech …

Continue Reading →